Open access · US-GOV
via ClinicalTrials.gov Clinical trial
Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study)
Authors not listed
California Retina Consultants · 2019
Abstract
To compare the efficacy and comfort of two FDA approved pre-injection antiseptics when used for intravitreal injections.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- ClinicalTrials.gov
- Canonical
- link ↗
- Fetched
- 2026-11-02 MST
Cite this
APA
Anonymous. (2019). Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study). <em>California Retina Consultants</em>. https://clinicaltrials.gov/study/NCT04018482
Vancouver
Anonymous. Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study). California Retina Consultants. 2019.
BibTeX
@misc{anon2019Povido,
title = {Povidone Iodine vs AVEnova: A Pre-injection Disinfection Study (PAVE Study)},
author = {Anonymous},
journal = {California Retina Consultants},
year = {2019},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
University of California, San Francisco 2013
Open access · US-GOV
The Effect of a Short Term Meditation Retreat on Markers of Cellular Stress and Aging
Weinkle, Susan H., M.D. 2009
Open access · US-GOV
Safety and Efficacy of the Addition of 0.3% Lidocaine With EVOLENCE®
Medy-Tox 2016
Open access · US-GOV
Clinical Study of Neuramis® Volume Lidocaine to Evaluate the Efficacy and Safety for Temporary Restoring the Mid-face Volume
Dr.dr.Irma Bernadette, SpKK (K) 2021
Open access · US-GOV
Effectivity of 1 Finger Tip Unit Compared to 2 Finger Tip Units 0.05% Tretinoin Cream Before and After 30% Trichloroacetic Acid Chemical Peeling on Aging Skin
Opthea Limited 2017
Open access · US-GOV
A Dose-Ranging Study of Intravitreal OPT-302 in Combination With Ranibizumab, Compared With Ranibizumab Alone, in Participants With Neovascular Age-Related Macular Degeneration (Wet AMD)
Ove Andersen 2023
Open access · US-GOV